{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:22:39Z","timestamp":1792041759975,"version":"4.4.0"},"reference-count":22,"publisher":"Japan Neurosurgical Society","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.2176\/jns-nmc.2022-0298","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:14:11Z","timestamp":1679595251000},"page":"61-66","source":"Crossref","is-referenced-by-count":6,"title":["Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report"],"prefix":"10.2176","volume":"10","author":[{"given":"Yurie","family":"RAI","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"HARA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Toranomon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) O&apos;Hare T, Deininger MWN, Eide CA, Clackson T, Druker BJ: Targeting the BCR-ABL signaling pathway in therapy-resistant philadelphia chromosome-positive leukemia. <i>Clin Cancer Res<\/i> 17: 212-221, 2011","DOI":"10.1158\/1078-0432.CCR-09-3314"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Shimoni A, Volchek Y, Koren-Michowitz M, et al.: Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia: Nilotinib After SCT in CML or Ph <sup>+<\/sup> ALL. <i>Cancer<\/i> 121: 863-871, 2015","DOI":"10.1002\/cncr.29141"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Giebel S, Czyz A, Ottmann O, et al.: Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the: TKIs After AlloHSCT in Ph+ ALL. <i>Cancer<\/i> 122: 2941-2951, 2016","DOI":"10.1002\/cncr.30130"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Aichberger KJ, Herndlhofer S, Schernthaner GH, et al.: Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. <i>Am J Hematol<\/i> 86: 533-539, 2011","DOI":"10.1002\/ajh.22037"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Uemura M, Kanazawa M, Yamagishi T, et al.: Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib. <i>J Neurol Sci<\/i> 408: 116577, 2020","DOI":"10.1016\/j.jns.2019.116577"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Suzuki K, Yamamoto J, Kakeda S, et al.: Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: A case report. <i>Mol Clin Oncol<\/i> 2018. doi: 10.3892\/mco.2018.1780","DOI":"10.3892\/mco.2018.1780"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Alshiekh-Nasany R, Zidan A, Martinez C: Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib. <i>Clin Case Rep<\/i> 4: 1184-1186, 2016","DOI":"10.1002\/ccr3.729"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Fujiwara S, Fukumoto S, Miyazaki Y, et al.: A case of multiple arterial stenoses due to long-term nilotinib exposure. <i>Jpn J Neurosurg<\/i> 30: 804-810, 2021","DOI":"10.7887\/jcns.30.804"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Blay JY, von Mehren M: Nilotinib: A novel, selective tyrosine kinase inhibitor. <i>Semin Oncol<\/i> 38: S3-S9, 2011","DOI":"10.1053\/j.seminoncol.2011.01.016"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hochhaus A, Saglio G, Hughes TP, et al.: Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. <i>Leukemia<\/i> 30: 1044-1054, 2016","DOI":"10.1038\/leu.2016.5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD: Nilotinib treatment-associated cerebrovascular disease and stroke. <i>Am. J. Hematol<\/i> 88: 534-535, 2013","DOI":"10.1002\/ajh.23442"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M: Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia. <i>Interv Neuroradiol<\/i> 23: 527-530, 2017","DOI":"10.1177\/1591019917710810"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chen CJ, Sorace BJ, Shakeri A, et al.: Republished: Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. <i>J Neuro Interventional Surg<\/i> 10: e28, 2018","DOI":"10.1136\/neurintsurg-2018-013777.rep"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nakaya A, Ebitani M, Monzen T, et al.: A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemia. <i>Rinsho Shinkeigaku<\/i> 59: 418-424, 2019","DOI":"10.5692\/clinicalneurol.cn-001222"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Medeiros BC, Possick J, Fradley M: Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. <i>Blood Rev<\/i> 32: 289-299, 2018","DOI":"10.1016\/j.blre.2018.01.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Morris NT, Taylor MB, Hacobian M, et al.: Isolated pulmonary vasculitis associated with nilotinib use: a case report. <i>Leuk Res Rep<\/i> 14: 100214, 2020","DOI":"10.1016\/j.lrr.2020.100214"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Manley PW, Drueckes P, Fendrich G, et al.: Extended kinase profile and properties of the protein kinase inhibitor nilotinib. <i>Biochim Biophys Acta BBA - Proteins Proteomics<\/i> 1804: 445-453, 2010","DOI":"10.1016\/j.bbapap.2009.11.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Franco C, Ahmad PJ, Hou G, Wong E, Bendeck MP: Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1. <i>Circ Res<\/i> 106: 1775-1783, 2010","DOI":"10.1161\/CIRCRESAHA.109.213637"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kitamura Y, Tsujimura T, Jippo T, Hasugai T, Kanakura Y: Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. <i>Int Arch Allergy Immunol<\/i> 107: 54-56, 1995","DOI":"10.1159\/000236929"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Valent P, Baghestanian M, Bankl HC, et al.: New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. <i>Thromb Haemost<\/i> 87: 786-790, 2002","DOI":"10.1055\/s-0037-1613084"},{"key":"21","unstructured":"21) Jager NGL, Stuurman FE, Baars JW, Opdam FL: Cerebrovascular events during nilotinib treatment. <i>Neth J Med<\/i> 72: 2, 2014"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) G\u00f3mez-Galv\u00e1n JB, Borrego S, Tovar N, Llull L: Nilotinib as a risk factor for ischaemic stroke: a series of three cases. <i>Neurol Engl Ed<\/i> 32: 411-413, 2017","DOI":"10.1016\/j.nrleng.2015.11.011"}],"container-title":["NMC Case Report Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/10\/0\/10_2022-0298\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T01:11:00Z","timestamp":1679706660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/10\/0\/10_2022-0298\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":22,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2022-0298","relation":{},"ISSN":["2188-4226"],"issn-type":[{"value":"2188-4226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,31]]},"article-number":"2022-0298"}}